Robert E. Weibel

3.0k total citations
72 papers, 2.1k citations indexed

About

Robert E. Weibel is a scholar working on Epidemiology, Immunology and Infectious Diseases. According to data from OpenAlex, Robert E. Weibel has authored 72 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Epidemiology, 26 papers in Immunology and 21 papers in Infectious Diseases. Recurrent topics in Robert E. Weibel's work include Virology and Viral Diseases (41 papers), Respiratory viral infections research (18 papers) and Vaccine Coverage and Hesitancy (18 papers). Robert E. Weibel is often cited by papers focused on Virology and Viral Diseases (41 papers), Respiratory viral infections research (18 papers) and Vaccine Coverage and Hesitancy (18 papers). Robert E. Weibel collaborates with scholars based in United States and Switzerland. Robert E. Weibel's co-authors include M. R. Hilleman, Eugene B. Buynak, A. A. McLean, Joseph Stokes, A. F. Woodhour, B. J. Neff, Philip P. Vella, Barbara J. Kuter, Harry A. Guess and James E. Whitman and has published in prestigious journals such as New England Journal of Medicine, JAMA and PEDIATRICS.

In The Last Decade

Robert E. Weibel

70 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert E. Weibel United States 25 1.8k 483 449 346 268 72 2.1k
A. A. McLean United States 22 1.2k 0.7× 279 0.6× 195 0.4× 242 0.7× 135 0.5× 37 1.5k
Paul D. Parkman United States 21 1.6k 0.9× 607 1.3× 189 0.4× 246 0.7× 160 0.6× 51 2.0k
Mary L. Kumar United States 27 1.6k 0.9× 776 1.6× 147 0.3× 216 0.6× 142 0.5× 52 2.1k
Stephen R. Preblud United States 20 1.2k 0.7× 396 0.8× 563 1.3× 139 0.4× 128 0.5× 34 1.6k
S. A. Plotkin United States 22 1.5k 0.8× 1.1k 2.3× 98 0.2× 314 0.9× 306 1.1× 55 2.3k
M Just Switzerland 24 1.0k 0.6× 356 0.7× 92 0.2× 349 1.0× 140 0.5× 86 1.7k
Linda L. Yasukawa United States 26 1.4k 0.8× 910 1.9× 196 0.4× 493 1.4× 97 0.4× 38 2.1k
C. J. White United States 20 1.1k 0.6× 345 0.7× 74 0.2× 245 0.7× 254 0.9× 26 1.5k
Gregory A. Poland United States 30 1.3k 0.7× 667 1.4× 272 0.6× 772 2.2× 155 0.6× 54 2.3k
Saul Krugman United States 34 3.0k 1.7× 1.0k 2.1× 570 1.3× 606 1.8× 126 0.5× 103 4.0k

Countries citing papers authored by Robert E. Weibel

Since Specialization
Citations

This map shows the geographic impact of Robert E. Weibel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Weibel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Weibel more than expected).

Fields of papers citing papers by Robert E. Weibel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Weibel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Weibel. The network helps show where Robert E. Weibel may publish in the future.

Co-authorship network of co-authors of Robert E. Weibel

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Weibel. A scholar is included among the top collaborators of Robert E. Weibel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Weibel. Robert E. Weibel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rorke‐Adams, Lucy B., Geoffrey Evans, Robert E. Weibel, & Rosemary Johann‐Liang. (2011). Neuropathology of vaccination in infants and children. Vaccine. 29(47). 8754–8759. 3 indexed citations
2.
Weibel, Robert E., et al.. (1996). Reporting vaccine-associated paralytic poliomyelitis: concordance between the CDC and the National Vaccine Injury Compensation Program.. American Journal of Public Health. 86(5). 734–737. 9 indexed citations
3.
4.
Kuter, Barbara J., Robert E. Weibel, Harry A. Guess, et al.. (1991). Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine. 9(9). 643–647. 158 indexed citations
5.
Stahel, Rolf A., Carl O’Hara, Robert E. Weibel, & Alexander Martin. (1988). Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma. International Journal of Cancer. 41(2). 218–223. 38 indexed citations
6.
Weibel, Robert E., B. J. Neff, Barbara J. Kuter, et al.. (1984). Live Attenuated Varicella Virus Vaccine. New England Journal of Medicine. 310(22). 1409–1415. 309 indexed citations
7.
Arbeter, Allan M., Stuart E. Starr, Robert E. Weibel, & Stanley A. Plotkin. (1982). Live attenuated varicella vaccine: Immunization of healthy children with the OKA strain. The Journal of Pediatrics. 100(6). 886–893. 38 indexed citations
8.
Hilleman, M. R., A. A. McLean, Philip P. Vella, Robert E. Weibel, & A. F. Woodhour. (1978). Polyvalent pneumococcal polysaccharide vaccines.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 56(3). 371–5. 25 indexed citations
9.
Buynak, Eugene B., et al.. (1976). Long-Term Persistence of Antibody following Enders' Original and More Attenuated Live Measles Virus Vaccine. Experimental Biology and Medicine. 153(3). 441–443. 4 indexed citations
10.
Weibel, Robert E., V. M. Villarejos, Philip P. Vella, et al.. (1976). Clinical and Laboratory Investigations of Monovalent and Combined Meningococcal Polysaccharide Vaccines, Groups A and C. Experimental Biology and Medicine. 153(3). 436–440. 12 indexed citations
11.
Villarejos, V. M., et al.. (1971). Combined live measles-rubella virus vaccine. The Journal of Pediatrics. 79(4). 599–604. 10 indexed citations
12.
Weibel, Robert E., A. F. Woodhour, J Stokes, et al.. (1970). New metabolizable immunologic adjuvant for human use. The American Journal of Medicine. 48(4). 464–471. 9 indexed citations
13.
Weibel, Robert E., Eugene B. Buynak, Joseph Stokes, & M. R. Hilleman. (1970). PERSISTENCE OF IMMUNITY FOUR YEARS FOLLOWING JERYL LYNN STRAIN LIVE MUMPS VIRUS VACCINE. PEDIATRICS. 45(5). 821–826. 7 indexed citations
14.
Weibel, Robert E., et al.. (1969). Jeryl Lynn strain live mumps virus vaccine.. JAMA. 207(9). 1 indexed citations
15.
Weibel, Robert E.. (1969). Live Rubella Vaccines in Adults and Children. American journal of diseases of children. 118(2). 226–226. 32 indexed citations
16.
Weibel, Robert E., et al.. (1969). CLINICAL LABORATORY EXPERIENCES WITH A MORE ATTENUATED ENDERS' MEASLES VIRUS VACCINE (MORATEN) COMBINED WITH SMALLPOX VACCINE. PEDIATRICS. 43(4). 567–572. 1 indexed citations
17.
Weibel, Robert E.. (1968). Live Attenuated Rubella Virus Vaccines Prepared in Duck Embryo Cell Culture. JAMA. 205(8). 554–554. 11 indexed citations
18.
Hilleman, M. R., et al.. (1967). Rhinovirus Infection in Nursery and Kindergarten Children. New Rhinovirus Serotype 54. Experimental Biology and Medicine. 124(3). 845–850. 4 indexed citations
19.
Sweet, B. H., A. A. Tytell, Robert E. Weibel, et al.. (1966). Respiratory Virus Vaccines. III. Pentavalent Respiratory Syncytial-Parainfluenza Mycoplasma pneumoniae Vaccine.. American Review of Respiratory Disease. 94(3). 2 indexed citations
20.
Stokes, J, et al.. (1962). Persistent Immunity Following Enders Live, Attenuated Measles-Virus Vaccine Given with Human Immune Globulin. New England Journal of Medicine. 267(5). 222–224. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. A. McLean Breakdown of academic impact, for papers by Paul D. Parkman Breakdown of academic impact, for papers by Mary L. Kumar Breakdown of academic impact, for papers by Stephen R. Preblud Breakdown of academic impact, for papers by S. A. Plotkin Breakdown of academic impact, for papers by M Just Breakdown of academic impact, for papers by Linda L. Yasukawa Breakdown of academic impact, for papers by C. J. White Breakdown of academic impact, for papers by Gregory A. Poland Breakdown of academic impact, for papers by Saul Krugman
Rankless by CCL
2026